Alamar Biosciences (ALMR) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
TransMedics Group is the larger company by market cap ($2.74 billion vs $1.80 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMR | TMDX |
|---|---|---|
| Share price | $25.91 | $79.00 |
| Market cap | $1.80B | $2.74B |
| 1-day change | -6.70% | -2.55% |
| YTD return | — | -35.06% |
| 1-year return | — | -33.08% |
| 5-year return | — | +205.35% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | — | 35.05 |
| EPS (TTM) | $-1.20 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $39.61 | $156.00 |
| 52-week low | $18.85 | $60.11 |
| Distance from 52-week high | -34.59% | -49.36% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +36.63% | +26.35% |
| Average volume | 399.23K | 815.54K |
| Shares outstanding | 69.39M | 34.68M |
| Employees | 286 | 898 |
| Sector | Industrials | Healthcare |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Alamar Biosciences in Industrials and TransMedics Group in Healthcare.
About Alamar Biosciences
ALMR stock →Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers.
Industrials · Biotechnology: Laboratory Analytical Instruments · 286 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
ALMR vs TMDX FAQ
Which is bigger, Alamar Biosciences or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $1.80B for Alamar Biosciences (ALMR).
Are Alamar Biosciences and TransMedics Group in the same industry?
No. Alamar Biosciences is in the Industrials sector, while TransMedics Group is in Healthcare.